Amrize revises prior-period financial statements after identifying immaterial misstatements
AMRZ•Revised statements correct prior-period misstatements
Amrize published revised financial statements for 2025 and interim 2025–26 periods to correct prior-period misstatements found in the June 30, 2026 quarter.
The largest correction involved understated extended-warranty deferred revenue tied to the Duro-Last and Malarkey acquisitions; it totaled $78 million at Dec. 31, 2025.
Revisions lowered March 31, 2025 net loss to $94 million from $87 million; March 31, 2026 net loss improved to $107 million from $118 million.
June 30, 2025 quarter net income was revised to $416 million from $428 million; six-month net income was revised to $322 million from $341 million.
Dec. 31, 2025 total assets were revised to $24.21 billion from $24.25 billion; total equity was revised to $13.12 billion from $13.25 billion.
